Harr Steve 4

4 · Sana Biotechnology, Inc. · Filed Mar 10, 2026

AI-generated summary of this filing

Updated Mar 10, 2026

Sana (SANA) CEO Steve Harr Exercises RSUs, Surrenders 24,345 Shares

What Happened

Steve Harr, President, Chief Executive Officer and Director of Sana Biotechnology (SANA), had restricted stock units convert into common shares (reported as exercise/conversion of a derivative). He acquired 41,666 shares on 2026-03-06 and 50,000 shares on 2026-03-07 (total 91,666) at $0.00 per share.
To cover tax withholding, 11,526 shares were surrendered on 2026-03-09 at $3.13/share and 12,819 shares were surrendered on 2026-03-09 at $3.10/share, generating cash proceeds of about $36,076 and $39,739 respectively (total ≈ $75,815). Net shares retained from these conversions = 91,666 − 24,345 = 67,321 shares.

Key Details

Transaction dates: conversions on 2026-03-06 and 2026-03-07; tax withholding/surrender on 2026-03-09. Filing date: 2026-03-10 (appears timely under the SEC two-business-day rule).
Transaction codes: M = exercise/conversion of derivative (here, RSUs converting to common stock); F = payment of exercise price or tax liability (shares withheld/surrendered).
Shares surrendered for tax withholding: 24,345 shares for ~$75,815 total.
Shares owned after the transaction: not specified in the provided filing excerpt.
Footnotes: F1 — certain shares are held in trusts for immediate-family beneficiaries; F2 — each RSU equals one contingent share; F3/F4 — describe vesting schedules (portions vested on March 6/7, 2026 with remaining installments in later years).

Context

This is a routine vesting + tax-withholding transaction (not an open-market sale). Converting RSUs at $0 reflects vesting, and surrendering shares to cover taxes is a common cashless withholding method that does not necessarily indicate a change in insider sentiment.

Form 4

Period: 2026-03-06

DirectorPresident & CEO

Transactions

Exercise/Conversion
Common Stock
2026-03-06+41,666→ 7,918,596 total
Exercise/Conversion
Common Stock
2026-03-07+50,000→ 7,968,596 total
Tax Payment
Common Stock
2026-03-09$3.13/sh−11,526$36,076→ 7,957,070 total
Tax Payment
Common Stock
2026-03-09$3.10/sh−12,819$39,739→ 7,944,251 total
Exercise/Conversion
Restricted Stock Units
[F2][F3]
2026-03-06−41,666→ 125,001 total
→ Common Stock (41,666 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F4]
2026-03-07−50,000→ 100,000 total
→ Common Stock (50,000 underlying)

Holdings

Footnotes (4)

[F1]Brian L. Harr is the trustee of these trusts, whose sole beneficiaries are members of the reporting person's immediate family.
[F2]Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
[F3]The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
[F4]The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

Signature

/s/ Aaron M. Grossman, Attorney-in-Fact for Steve Harr|2026-03-10

1 file